Ticker

HIGHLIGHTS Mature data from Amplia's ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meeting The ACCENT trial investigates the combination of narmafotinib with standard-of-care chemotherapy The data presented includes additional analysis of the promising efficacy and survival data reported last month Melbourne, Australia, April 22, 2026…

Altona Rare Earths, the London-listed critical materials explorer, saw its shares rise 11% to 3.11 pence on Tuesday after reporting that gallium...

Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF)'s ACCENT trial has reached an important milestone after an independent central review confirmed five complete...

US nuclear technology developer X‑Energy has filed paperwork with the Securities and Exchange Commission to launch an initial public offering on Nasdaq,...

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at…